Abstract:Funding Acknowledgements Type of funding sources: None. Main funding source(s): none Aims To evaluate the effect and safety of in-hospital use of the proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitor on blood lipid levels in the acute coronary syndrome (ACS) patients. Methods We searched the PubMed, MEDLINE, Web of Science, Ovid and Cochrane Library electronic databases through July 2023 to identify randomized controlled trials (RCTs) and cohort studies using PCSK9 inhibitors during ACS hospitalization. Then we compared the PCSK9 inhibitor group with a placebo or a blank control group with the same background of lipid-lowering therapy. Two reviewers independently screened the literature, extracted data, and evaluated the risk of bias for the included studies. A software was used to analyze the changes in overall lipids from baseline and the adverse event rates. Results A total of 15 studies enrolling 3891 patients with ACS were eligible, including 10 RCTs (n = 1406) and 5 cohort studies (n = 2485). Treatment with PCSK9 inhibitors showed a greater reduction in low-density lipoprotein cholesterol (LDLC) (SMD=1.46, 95% CI: 1.16-1.76, P<0.01). The cumulative meta-analysis of follow-up time showed that the degree of LDLC reduction stabilized after 12 weeks (SMD=1.42 at 12 weeks, 95% CI: 1.06-1.79, P<0.01), and thus, PCSK9 inhibitors dramatically decreased LDLC levels in comparison to controls at both ≤12 weeks and 12–72 weeks. The LDLC levels with PCSK9 inhibitors that reached the recommended standards of AHA/ACC (≤1.8mmol/l) and ESC (≤1.4mmol/l) were 95% and 80% respectively, which were significantly higher than those of the control group (58% and 22%). PCSK9 inhibitors can also reduce the total cholesterol, triglycerides, apolipoprotein B, and lipoprotein (a), while increasing the high-density lipoprotein cholesterol, but they have no statistical significance in reducing apolipoprotein A1. Compared with placebo or blank control, the addition of PCSK9 inhibitor did not increase the occurrence of adverse events (RR =-0.01,95% CI:-0.19-0.18, P = 0.95) and serious adverse events (RR =-0.03, 95% CI:-0.48-0.43, P=0.91). Conclusion In-hospital use of PCSK9 inhibitors can significantly improve the blood lipid levels of ACS patients and increase the target LDLC attainment rate, with satisfactory safety and good tolerance.

MK-0616: an oral PCSK9 inhibitor for hypercholesterolemia treatment

New Oral PCSK9 Inhibitor: “MK-0616”

Oral PCSK9 Inhibitors

Vaccines Targeting PSCK9 for the Treatment of Hyperlipidemia

Lipid Lowering Therapy and Circulating PCSK9 Concentration

Current Phase II proprotein convertase subtilisin/kexin 9 inhibitor therapies for dyslipidemia

A Review of PCSK9 Inhibitors and Their Effects on Cardiovascular Diseases

Meta-analysis of clinical outcomes of PCSK9 modulators in patients with established ASCVD

PCSK9 inhibitors: A new era of lipid lowering therapy

Clinical Advances in Monoclonal Antibody Against PCSK9 for Coronary Atherosclerotic Heart Disease

PCSK9 Inhibition-Based Therapeutic Approaches: an Immunotherapy Perspective.

Proprotein Convertase Subtilism/kexin Type 9 Inhibitors: a New Strategy of Regulating Cholesterol

Long-Term Efficacy and Tolerability of PCSK9 Targeted Therapy: A Review of the Literature

PCSK9 Inhibition: From Current Advances to Evolving Future

Effect of PCSK9 on Atherosclerotic Cardiovascular Diseases and Its Mechanisms: Focus on Immune Regulation

Proprotein Convertase Subtilisin/Kexin type 9 (PCSK9): Impact of PCSK9 on Major Adverse Cardiac and Cerebrovascular Events

PCSK9 Inhibitors in Secondary Prevention-An Opportunity for Personalized Therapy

Efficacy and safety of PCSK9 inhibition in cardiovascular disease: a meta-analysis of 45 randomized controlled trials

PCSK9 inhibitors in real life-Cardiometabolic risk management in dyslipidemic patients in Vienna

Real-world effectiveness of monoclonal antibody inhibitors of PCSK9 in patients with heterozygous familial hypercholesterolemia: A retrospective cohort study

Effect and safety of PCSK9 inhibitor in-hospital use on blood lipid level in the ACS patients: a systematic review and meta-analysis